Business Context and Reporting Period
This Form 8-K Current Report was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on August 9, 2021. The filing discloses the entry into a Material Definitive Agreement for a registered direct offering of common stock and warrants. The company is a Delaware corporation headquartered in Waltham, MA, focused on research and development of pharmaceutical products.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than periodic financial performance metrics such as revenue or operating profit. Key transaction figures include:
- Shares Sold: 4,668,844 shares of Common Stock.
- Offering Price: $2.3025 per share.
- Warrants Issued: 2,334,422 warrants (50% of shares sold) with an exercise price of $2.24 per share, exercisable for 5.5 years.
- Gross Proceeds: Approximately $10.75 million (before fees and expenses).
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee on gross proceeds, plus warrants to purchase 233,442 shares (5% of aggregate shares sold) at $2.8781 per share.
- Other Expenses: $75,000 non-accountable expenses and $15,950 clearing fees.
Material Changes Versus Prior Period
This filing represents a discrete capital event and does not provide comparative financial data (e.g., revenue or net income) against a prior period. The primary material change is the increase in outstanding equity and the dilution resulting from the issuance of new shares and warrants.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds to support operations, specifically for:
- Clinical trials.
- Working capital.
- General corporate purposes, including research and development efforts.
- Potential acquisition or in-licensing of other products, candidates, or technologies.
- Verify the final closing date and actual net proceeds received after deducting all placement agent fees and expenses.
- Confirm the updated total share count and the impact of the new shares and warrants on existing shareholder dilution.
- Review the specific terms of the warrants, including adjustment provisions and exercise windows.
- Monitor future filings for the specific allocation of proceeds to clinical trials versus general corporate purposes.
The company has not yet determined the specific allocation of funds among these purposes. The closing of the transaction was expected on or about August 11, 2021.